Clinical trial Recruiting at 1 site Interventional Ages 1 Year to 99

See if a home diabetes screening kit helps people at risk for type 1 diabetes

Official title: Finding Immune Nascent Type 1 Diabetes (FIND T1D)

Run by Indiana University · NCT07663136 · Data updated 2026-11-12

This study tests whether email or mail outreach versus phone follow-up more effectively prompts Indiana Biobank participants to complete a Type 1 diabetes home screening kit.

More Type 1 Diabetes (T1D) trials

Quick facts

Study typeInterventional
Ages1 Year to 99 Years
SexAll
Enrollment3800 (estimated)
SponsorIndiana University
Academic / other
Locations1 site (Indianapolis, Indiana)
StatusRecruiting
StartedJuly 28, 2026
Main results expectedJune 2029
Study endsJune 2029
Registry record updatedOctober 2, 2026
Trial IDNCT07663136 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Indiana Biobank participants who can consent and are aged 1–99 (including pregnant women) are potential candidates for the home screening portion.

Probably not a fit

Participants who refuse consent for home screening or have conditions excluding autoantibody screening may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers compare two recruitment approaches to see which yields higher completion of a Type 1 diabetes home screening kit among participants connected through the Indiana Biobank. The trial uses low-touch (email/mail) versus high-touch (phone contact and staff follow-up) communication methods. Participants in Indiana Biobank who consent can receive a home screening kit for Type 1 diabetes; eligibility includes broad age range (1–99) and pregnancy status, with exclusions for those who refuse consent for home screening or have active diabetes conditions that would preclude autoantibody screening. The study is led by Indiana University with collaboration from Sanofi and sites at Indiana University School of Medicine in Indianapolis. Interventions involve contacting participants by phone or email/mail to offer completion of the kit.

Why it matters

Potential benefit: If successful, the findings could guide more effective recruitment strategies to identify individuals at risk for Type 1 diabetes.

How similar studies have gone: Prior work supports that tailored recruitment approaches can influence participation rates, but this specific comparison of contact methods is novel in this context.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participant must be in Indiana Biobank
* Participant must be able to provide consent
* Ages 1-99 including pregnant women

Exclusion Criteria:

* Refusal to sign informed consent for home screening is exclusionary for the home screening portion of the study
* While other medical conditions are allowable prior diabetes diagnosis is exclusionary for home autoantibody screening

Where it's running

  • Indiana University School of Medicine
    Indianapolis, Indiana, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.